Spots Global Cancer Trial Database for testicular lymphoma

Every month we try and update this database with for testicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	NCT00088881	Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... Waldenström Mac...	rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi...	18 Years -	National Cancer Institute (NCI)
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	NCT00054639	Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	oblimersen sodi... rituximab laboratory biom...	18 Years -	National Cancer Institute (NCI)
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	NCT02213913	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac...	lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom...	18 Years -	University of Chicago
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT00720135	Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Small Intestine... Splenic Margina... Testicular Lymp... Waldenstrom Mac...	DI-Leu16-IL2 im... rituximab flow cytometry immunohistochem... pharmacological... laboratory biom... enzyme-linked i... reverse transcr...	18 Years - 65 Years	City of Hope Medical Center
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	NCT00088881	Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... Waldenström Mac...	rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi...	18 Years -	National Cancer Institute (NCI)
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT00720135	Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Small Intestine... Splenic Margina... Testicular Lymp... Waldenstrom Mac...	DI-Leu16-IL2 im... rituximab flow cytometry immunohistochem... pharmacological... laboratory biom... enzyme-linked i... reverse transcr...	18 Years - 65 Years	City of Hope Medical Center
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	NCT02109224	Adult B Acute L... Chronic Lymphoc... Cutaneous B-Cel... Extranodal Marg... HIV Infection Intraocular Lym... Multicentric An... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Refractory Hair... Refractory Plas... Small Intestina... Splenic Margina... Testicular Lymp... Waldenstrom Mac...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	NCT00089076	Adult Grade III... B-cell Chronic ... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	ipilimumab laboratory biom...	18 Years -	National Cancer Institute (NCI)
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	NCT00088881	Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... Waldenström Mac...	rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: